17 results on '"Molitoris, Jason K."'
Search Results
2. Radiation Therapy and Malignant Fistulae of Anorectal Cancers.
- Author
-
Koroulakis, Antony I., Molitoris, Jason K., Sullivan, Michael, Jiang, Yixing, Hausner, Petr F., Hanna, Nader, Bafford, Andrea, Miller, Robert C., and Regine, William F.
- Abstract
Although fistulization is a well-studied late toxic effect of radiation therapy (RT), anorectal cancers (ARCs) can present with malignant fistulae (MF) and negatively affect quality of life. The effect of RT, often combined with concurrent chemotherapy, on MF needs systematic analysis, because practitioners are concerned that RT may exacerbate MF. We reviewed our institutional series evaluating the hypothesis that RT worsens MF. A single-institutional retrospective analysis of patients with ARC receiving RT from 2006 to 2019 was performed. These patients were screened for MF. Any MF resected before RT and RT not directed at the site of MF were excluded. Effects were assessed by review of available follow-up documentation and imaging. A total of 639 patients with ARC were reviewed, and 47 had MF (7.4%). With a median follow-up of 22 months (range, 2-133 months), RT improved MF in 17 of 29 evaluable patients (59%), with 9 of 29 (31.0%) having resolution. The median time to improvement was 50 days (range, 25-117 days); the median duration of improvement was 161 days (range, 0-1941 days). Malignant fistulae persisted in 12 of 29 patients (41%), with persistent local disease in all cases; in 2 cases, MF worsened concomitant with local progression. In all, 7.4% of patients with ARC presented with MF. Radiation therapy led to improvement or resolution in more than half of evaluable patients. Persistence or worsening of MF was only observed in patients with refractory or progressive local disease. Based on our findings, MF is not a contraindication to RT and may be considered as an independent indication for palliative RT. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. 227 Early outcomes for a single-arm, single-stage phase I/II trial of Selective Avoidance of nodalVolumEs at minimal Risk (SAVER) in the contralateral neck of patients with p16-positiveoropharynx cancer.
- Author
-
Witek, Matthew E, Molitoris, Jason K, Mehra, Ranee, Taylor, Rodney J, Regine, William, and Hatten, Kyle M
- Subjects
- *
CANCER patients , *PROTON therapy , *SURGICAL robots , *PAROTID glands , *RADIOTHERAPY - Abstract
Most patients with p16-positive oropharynx cancer (p16+OPC) receive elective nodal radiation therapy that improves regional control but increases acute and long-term toxicity. We evaluated the efficacy and toxicity profile of a reduced contralateral elective nodal volume in patients with p16+OPC receiving definitive or adjuvant radiation therapy. Patients with newly diagnosed p16+OPC without contralateral nodal involvement treated with primary proton or photon-based (chemo)radiation therapy or adjuvant (chemo)radiation therapy following transoral robotic surgery (TORS) were eligible for enrollment. The reduced contralateral nodal volume included high-risk regions of levels II and III1. The primary endpoint was elective out-of-field contralateral nodal failure. Dosimetric studies comparing standard versus reduced elective nodal volumes were analyzed with the t-test. Acute toxicity was collected using CTCAE v4.0. Fifty-two patients were enrolled of which 36 (69.2%) received definitive (chemo)radiation therapy. Sixteen (30.8%) patients underwent adjuvant radiation therapy following TORS of which 5 (31.2%) received concurrent chemotherapy. Proton therapy was used in 38 (73.1%) of patients. There were no elective nodal failures at a median follow up of 15 months (range 1-24 months). For the first 20 patients enrolled, dosimetric comparison of the reduced contralateral elective nodal volume to a consensus elective nodal volume demonstrated a decrease in mean dose (14.1 Gy to 18.5 Gy [p<0.05]) and V30 Gy (11.6% to 21.3% [p<0.01]) of the contralateral parotid gland. Significant differences were independent of radiation modality or technology. Acute grade 3 toxicity was observed in 13 (25%) patients including 6 (11.5%) who received a gastrostomy tube during treatment. There were no grade 4-5 acute toxicities, and no patients with 6 months of follow up retained gastrostomy tube. Precise delivery of radiation therapy to high-risk areas for contralateral nodal disease results in excellent regional control regardless of treatment approach. Dose to contralateral organs at risk and toxicity profile were favorable. Longer follow-up is needed to further support this de-intensification strategy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Assessing Outcomes of Patients Treated With Re-Irradiation Utilizing Proton Pencil-Beam Scanning for Primary or Recurrent Malignancies of the Esophagus and Gastroesophageal Junction.
- Author
-
DeCesaris, Cristina M., McCarroll, Rachel, Mishra, Mark V., Glass, Erica, Greenwald, Bruce D., Carr, Shamus, Burrows, Whitney, Mehra, Ranee, Regine, William F., Simone II, Charles B., Choi, J. Isabelle, Molitoris, Jason K., and Simone, Charles B 2nd
- Published
- 2020
- Full Text
- View/download PDF
5. Optimal Target Delineation and Treatment Techniques in the Era of Conformal Photon and Proton Breast and Regional Nodal Irradiation.
- Author
-
Kowalski, Emily S., Feigenberg, Steven J., Cohen, Justin, Fellows, Zachary, Vadnais, Patrick, Rice, Stephanie, Mishra, Mark V., Molitoris, Jason K., Nichols, Elizabeth M., and Snider III, James W.
- Abstract
Regional nodal irradiation improves disease-free and distant disease–free survival in patients with high-risk breast cancer (BC). Trials demonstrating this used 2- or 3-dimensional conformal radiation therapy (2-dimensional or 3-dimensional [3D] conformal radiotherapy [CRT]) fields based on bony anatomy. Modern volumetric-modulated arc therapy (VMAT) and pencil beam scanning proton therapy (PBSPT) may underdose regional nodes (RNs) not contoured but covered by 3D CRT. Multiple atlases guide modern treatment planning. This study addresses the risk of underdosing when relying on published atlases and treating with 3D CRT, VMAT, and PBSPT. Targets per the Radiation Therapy Oncology Group (RTOG), European Society for Radiotherapy and Oncology (ESTRO), and Radiotherapy Comparative Effectiveness Consortium (RADCOMP) atlases were contoured on a representative patient CT scan. 3D CRT plans based on anatomic borders and VMAT and PBSPT plans for each set of target volumes were generated. Positron emission tomography/computed tomography (PET/CT) scans were reviewed. CT-positive and
18 F-fluorodeoxyglucose (18 F-FDG)–avid RNs (n = 389) were mapped from 102 patients with locally advanced (n = 51; median 2; range, 1-8 nodes) and metastatic (n = 51; median 4; range, 1-19 nodes) BC: axillary (AX; n = 284), supraclavicular (SCV; n = 60), and internal mammary nodal (IMN; n = 45).18 F-FDG-avid RNs falling within the 95% isodose line were considered adequately covered. 3D CRT plans provided excellent RN coverage. Low AX nodes were covered (≥99%) in all plans. Underdosing of18 F-FDG–avid RNs falling in the high AX (78%-92%), SCV (52%-75%), and IMN (84%-89%) volumes was observed following the RTOG and ESTRO atlases for VMAT and PBSPT plans. Use of the RADCOMP atlas provided coverage of these areas (89%-100%) with slightly increased heart and lung doses. Atlas guided VMAT/PBSPT plans provided cumulative nodal coverage as follows: ESTRO (89%/88%), RTOG (93%/91%), and RADCOMP (98%/96%). VMAT and PBSPT for regional nodal irradiation in patients with high-risk BC risks underdosage in the high AX, SCV, and IMN nodal regions unless comprehensive target delineation is performed. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
6. Lymph Node Size Predicts for Asymptomatic Brain Metastases in Patients With Non-small-cell Lung Cancer at Diagnosis.
- Author
-
Rice, Stephanie R., Molitoris, Jason K., Vyfhuis, Melissa A.L., Edelman, Martin J., Burrows, Whitney M., Feliciano, Josephine, Nichols, Elizabeth M., Suntharalingam, Mohan, Donahue, James, Carr, Shamus R., Friedberg, Joseph, Badiyan, Shahed, Simone II, Charles B., Feigenberg, Steven J., Mohindra, Pranshu, and Simone, Charles B 2nd
- Published
- 2019
- Full Text
- View/download PDF
7. Start Combining, Stop Comparing.
- Author
-
Molitoris, Jason K.
- Published
- 2023
- Full Text
- View/download PDF
8. Glucocorticoid Elevation of Dexamethasone-induced Gene 2 (Dig2/RTP8O1/REDD1) Protein Mediates Autophagy in Lymphocytes.
- Author
-
Molitoris, Jason K., McColl, Karen S., Swerdlow, Sarah, Matsuyama, Mieko, Minh Lam, Finkel, Terri H., Matsuyama, Shigemi, and Distelhorst, Clark W.
- Subjects
- *
GLUCOCORTICOIDS , *DEXAMETHASONE , *LYMPHOCYTES , *GENE expression , *RAPAMYCIN - Abstract
Glucocorticoid hormones, including dexamethasone, induce apoptosis in lymphocytes and consequently are used clinically as chemotherapeutic agents in many hematologic malignancies. Dexamethasone also induces autophagy in lymphocytes, although the mechanism is not fully elucidated. Through gene expression analysis, we found that dexamethasone induces the expression of a gene encoding a stress response protein variously referred to as Dig2, RTP801, or REDD1. This protein is reported to inhibit mammalian target of rapamycin (mTOR) signaling. Because autophagy is one outcome of mTOR inhibition, we investigated the hypothesis that Dig2/RTP801/REDD1 elevation contributes to autophagy induction in dexamethasone-treated lymphocytes. In support of this hypothesis, RNAi-mediated suppression of Dig2/RTP801/REDD1 reduces mTOR inhibition and autophagy in glucocorticoid-treated lymphocytes. We observed similar results in Dig2/Rtp801/Redd1 knock-out murine thymocytes treated with dexamethasone. Dig2/RTP801/REDD1 knockdown also leads to increased levels of dexamethasone-induced cell death, suggesting that Dig2/RTP801/REDD1-mediated autophagy promotes cell survival. Collectively, these findings demonstrate for the first time that elevation of Dig2/RTP801/REDD1 contributes to the induction of autophagy. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
9. Patterns of Care and Survival in Stage III NSCLC Among Black and Latino Patients Compared With White Patients.
- Author
-
Vyfhuis, Melissa A.L., Bentzen, Søren M., Molitoris, Jason K., Diwanji, Tejan, Badiyan, Shahed, Grover, Surbhi, Adebamowo, Clement A., Simone II, Charles B., Mohindra, Pranshu, and Simone, Charles B 2nd
- Published
- 2019
- Full Text
- View/download PDF
10. Racial Analysis of Clinical & Biochemical Outcomes in Prostate Cancer Patients Treated with Low-Dose-Rate Brachytherapy.
- Author
-
Kerans, Samuel J., Samanta, Santanu, Vyfhuis, Melissa A.L., Guerrero, Mariana, Bang, Christine Ko, Mishra, Mark V., Rana, Zaker, Amin, Pradip P., Kwok, Young, Naslund, Michael J., and Molitoris, Jason K.
- Subjects
- *
PROSTATE cancer , *PROSTATE cancer patients , *LOW dose rate brachytherapy , *CANCER prognosis , *TREATMENT effectiveness , *RADIOISOTOPE brachytherapy - Abstract
Purpose: Black men in the United States suffer significantly higher incidence of and mortality from prostate cancer (PCa) than non-Black men. The cause of this disparity is multifactorial, though inequitable access to curative radiation modalities, including low-dose-rate (LDR) brachytherapy, may contribute. Despite this, there are few analyses evaluating the potential of different radiation therapies to mitigate outcome disparities. Therefore, we examined the clinical outcomes of Black and non-Black patients treated with definitive LDR brachytherapy for prostate cancer.Methods: Data were collected for all patients treated with definitive LDR brachytherapy between 2005 and 2018 on a retrospective IRB-approved protocol. Pearson Chi-Squared analysis was used to assess demographic and cancer differences between Black and non-Black cohorts. Freedom from biochemical failure (FFBF) was calculated using Kaplan-Meier analysis. Univariate and multivariate analyses were used to identify factors predictive of biochemical failure.Results: One hundred and sixty-seven patients were included in the analysis (Black: n=81 [48.5%]) with a median follow-up of 88.4 months. Black patients were from lower income communities (P <0.01), had greater social vulnerability (P <0.01), and had a longer interval between diagnosis and treatment (P = 0.011). Overall cumulative FFBF was 92.3% (95% CI: 87.8% - 96.8%) at 5 years and 87.7% (95% CI: 82.0% - 93.4%) at 7 years. There was no significant difference in FFBF in Black and non-Black patients (P = 0.114) and Black race was not independently predictive of failure (HR 1.51 [95% CI: 0.56 - 4.01]; P = 0.42). Overall survival was comparable between racial groups (P = 0.972). Only nadir PSA was significantly associated with biochemical failure on MVA (HR = 3.57 [95% CI: 02.44 - 5.22]; P <0.001).Conclusions: Black men treated with LDR brachytherapy achieved similar FFBF to their non-Black counterparts despite poorer socioeconomic status. This suggests that PCa treatment with brachytherapy may eliminate some disparities clinical outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
11. Defining Optimal Target Volumes of Conformal Radiation Therapy for Diffuse Intrinsic Pontine Glioma.
- Author
-
Tinkle, Christopher L., Simone, Brittany, Chiang, Jason, Li, Xiaoyu, Campbell, Kristen, Han, Yuanyuan, Li, Yimei, Hover, Laura D., Molitoris, Jason K., Becksfort, Jared, Lucas, John T., Patay, Zoltan, Baker, Suzanne J., Broniscer, Alberto, Merchant, Thomas E., and Lucas, John T Jr
- Subjects
- *
OLIGODENDROGLIOMAS , *PROPORTIONAL hazards models , *RADIOTHERAPY , *GLIOMAS , *MAGNETIC resonance imaging , *PROGRESSION-free survival - Abstract
Purpose: Optimal radiation therapy (RT) target margins for diffuse intrinsic pontine glioma (DIPG) are unknown. We sought to define disease progression patterns in a contemporary cohort treated with conformal RT using different clinical target volume (CTV) margins.Methods and Materials: We reviewed 105 patients with newly diagnosed DIPG treated with conformal conventionally fractionated RT at our institution from 2006 to 2014. CTV margins were classified as standard (1 cm) for 60 patients and extended (2-3 cm) for 45 patients. Survival and cumulative incidence of progression in treatment groups were compared by log-rank and Gray's tests, respectively. Cox proportional hazard models identified predictors of survival.Results: For 97 patients evaluated with magnetic resonance imaging at progression, the cumulative incidences of isolated local, isolated distant, and synchronous disease progression at 1 year were 62.6%, 12.3%, and 7.2%, respectively, and did not differ significantly according to the CTV margin. Central dosimetric progression (Vprogression95% ≥95%) was observed in 80 of 81 evaluable patients. Median progression-free survival and overall survival (OS) were 7.6 months (95% confidence interval, 6.9-8.2) and 11.3 months (95% confidence interval, 10.0-12.8), respectively, and did not differ significantly according to margin status. DIPG survival prediction risk group (standard vs high, P = .02; intermediate vs high, P = .009) and development of distant metastasis (P = .003) were independent predictors of OS. For the 41 patients (39%) with a pathologic diagnosis, H3.3 K27M mutation was associated with shorter OS (hazard ratio [HR], 0.41; P =.02), whereas H3.1 K27M and ACVR1 mutations were associated with longer OS (HR, 3.56; P =.004 and HR, 2.58; P =.04, respectively).Conclusions: All patients who experienced local failure showed progression within the high-dose volume, and there was no apparent survival or tumor-control benefit to extending the CTV margins beyond 1 cm. Given the increasing use of reirradiation, standardizing the CTV margin to 1 cm may improve retreatment tolerance. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
12. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.
- Author
-
Agarwal, Manuj, Chhabra, Arpit M., Amin, Neha, Braccioforte, Michelle H., Molitoris, Jason K., and Moran, Brian J.
- Subjects
- *
RADIOISOTOPE brachytherapy , *PROSTATE cancer risk factors , *ANDROGEN drugs , *REGRESSION analysis , *CLINICAL trials - Abstract
Abstract Purpose The available data demonstrating that superiority of LDR brachytherapy (LDR-BT) boost in high-risk prostate cancer patients under represents patients with extracapsular extension (T3a) and/or seminal vesicle invasion (T3b) have been limited. We report long-term clinical outcomes data for patients with cT3a/b disease receiving LDR-BT. Methods and Materials Ninety-nine men (median age: 69.4 years) with cT3a/bN0M0 high-risk prostate adenocarcinoma received definitive LDR-BT or LDR-BT boost after external beam radiation therapy (EBRT) at a single institution between 1998 and 2007. About 86% of patients received androgen deprivation therapy. Freedom from biochemical failure (FFBF), prostate cancer–specific survival (PCSS), and overall survival (OS) was calculated using the Kaplan–Meier method with the Phoenix definition used as definition of failure. Cox regression analysis was used to compare outcomes between clinical stage, initial PSA, Gleason Score, and percent core positive rate. Results With a median followup of 7 years, 7-year rate of FFBF, PCSS, and OS for the entire cohort was 65.2% (±5.6%), 90.1% (±3.6%), and 77.9% (±4.7%), respectively. LDR-BT boost patients achieved a 7-year FFBF rate of 73.5 (±6.5%). No significant difference in outcomes was present between T3a or T3b disease, Gleason score, iPSA stratification and percent core positive rates. Conclusions LDR-BT, primarily as a boost in conjunction with ADT and EBRT, is not only feasible, but also highly effective in men with cT3a and cT3b high-risk prostate cancer resulting in excellent biochemical control and survival outcomes. LDR-BT boost implantation of patients should be strongly considered for cT3 patients given the merits of trimodality care. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases.
- Author
-
Sperduto, Paul W., Deegan, Brian J., Li, Jing, Jethwa, Krishan R., Brown, Paul D., Lockney, Natalie, Beal, Kathryn, Rana, Nitesh G., Attia, Albert, Tseng, Chia-Lin, Sahgal, Arjun, Shanley, Ryan, Sperduto, William A., Lou, Emil, Zahra, Amir, Buatti, John M., Yu, James B., Chiang, Veronica, Molitoris, Jason K., and Masucci, Laura
- Subjects
- *
CANCER radiotherapy , *RENAL cell carcinoma , *BRAIN metastasis , *CANCER invasiveness , *PROGNOSIS , *DIAGNOSIS , *ANTINEOPLASTIC agents , *BRAIN tumor treatment , *THERAPEUTIC use of cytokines , *CANCER treatment , *NEOVASCULARIZATION inhibitors , *BRAIN tumors , *CAUSES of death , *HEMOGLOBINS , *IMMUNOTHERAPY , *KIDNEY tumors , *MULTIVARIATE analysis , *RADIOSURGERY , *RADIOTHERAPY , *RETROSPECTIVE studies , *KARNOFSKY Performance Status , *THERAPEUTICS - Abstract
Purpose: To identify prognostic factors, define evolving patterns of care, and the effect of targeted therapies in a larger contemporary cohort of renal cell carcinoma (RCC) patients with new brain metastases (BM).Methods and Materials: A multi-institutional retrospective institutional review board-approved database of 711 RCC patients with new BM diagnosed from January 1, 2006, to December 31, 2015, was created. Clinical parameters and treatment were correlated with median survival and time from primary diagnosis to BM. Multivariable analyses were performed.Results: The median survival for the prior/present cohorts was 9.6/12 months, respectively (P < .01). Four prognostic factors (Karnofsky performance status, extracranial metastases, number of BM, and hemoglobin b) were significant for survival after the diagnosis of BM. Of the 6 drug types studied, only cytokine use after BM was associated with improved survival. The use of whole-brain radiation therapy declined from 50% to 22%, and the use of stereotactic radiosurgery alone increased from 46% to 58%. Nonneurologic causes of death were twice as common as neurologic causes.Conclusions: Additional prognostic factors refine prognostication in this larger contemporary cohort. Patterns of care have changed, and survival of RCC patients with BM has improved over time. The reasons for this improvement in survival remain unknown but may relate to more aggressive use of local brain metastasis therapy and a wider array of systemic treatment options for those patients with progressive extracranial tumor. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
14. Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA).
- Author
-
Sperduto, Paul W., Jiang, Wen, Brown, Paul D., Braunstein, Steve, Sneed, Penny, Wattson, Daniel A., Shih, Helen A., Bangdiwala, Ananta, Shanley, Ryan, Lockney, Natalie A., Beal, Kathryn, Lou, Emil, Amatruda, Thomas, Sperduto, William A., Kirkpatrick, John P., Yeh, Norman, Gaspar, Laurie E., Molitoris, Jason K., Masucci, Laura, and Roberge, David
- Subjects
- *
MELANOMA prognosis , *MELANOMA diagnosis , *BRAIN metastasis , *BIOMARKERS , *RETROSPECTIVE studies , *AGE distribution , *BRAIN tumors , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *MELANOMA , *PROGNOSIS , *REGRESSION analysis , *RESEARCH , *RESEARCH funding , *TRANSFERASES , *GENETIC markers , *EVALUATION research , *KARNOFSKY Performance Status - Abstract
Purpose: To update the Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for a markedly heterogeneous patient population, patients with melanoma and brain metastases, using a larger, more current cohort, including molecular markers.Methods: The original Melanoma-GPA is based on data from 483 patients whose conditions were diagnosed between 1985 and 2005. This is a multi-institutional retrospective database analysis of 823 melanoma patients with newly diagnosed brain metastases from January 1, 2006, to December 31, 2015. Multivariable analyses identified significant prognostic factors, which were weighted and included in the updated index (Melanoma-molGPA). Multiple Cox regression was used to select and weight prognostic factors in proportion to their hazard ratios to design the updated Melanoma-molGPA in which scores of 4.0 and 0.0 are associated with the best and worst prognoses, as with all of the diagnosis-specific GPA indices. Log-rank tests were used to compare adjacent classes.Results: There were 5 significant prognostic factors for survival (age, Karnofsky performance status [KPS], extracranial metastases [ECM], number of brain metastases, and BRAF status), whereas only KPS and the number of brain metastases were significant in the original Melanoma-GPA. Median survival improved from 6.7 to 9.8 months between the 2 treatment eras, and the median survival times for patients with Melanoma-molGPA of 0 to 1.0, 1.5 to 2.0, 2.5 to 3.0, and 3.5 to 4.0 were 4.9, 8.3, 15.8, and 34.1 months (P<.0001 between each adjacent group).Conclusions: Survival and our ability to estimate survival in melanoma patients with brain metastases has improved significantly. The updated Melanoma-molGPA, a user-friendly tool to estimate survival, will facilitate clinical decision making regarding whether and which treatment is appropriate and will also be useful for stratification of future clinical trials. To further simplify use, a free online/smart phone app is available at brainmetgpa.com. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
15. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.
- Author
-
Sperduto, Paul W., Jiang, Wen, Brown, Paul D., Braunstein, Steve, Sneed, Penny, Wattson, Daniel A., Shih, Helen A., Bangdiwala, Ananta, Shanley, Ryan, Lockney, Natalie A., Beal, Kathryn, Lou, Emil, Amatruda, Thomas, Sperduto, William A., Kirkpatrick, John P., Yeh, Norman, Gaspar, Laurie E., Molitoris, Jason K., Masucci, Laura, and Roberge, David
- Subjects
- *
CANCER treatment , *METASTASIS , *TREATMENT of brain cancer , *BRAIN cancer patients , *MELANOMA treatment , *PATIENTS - Abstract
Purpose: Brain metastases are a common problem in patients with melanoma, but little is known about the effect of gene mutations on survival in these patients.Methods and Materials: We created a retrospective multi-institutional database of 823 patients with melanoma and brain metastases diagnosed between 2006 and 2015. Clinical parameters, gene mutation status (BRAF, C-KIT, NRAS), and treatment were correlated with survival. Treatment patterns and outcomes were compared with a prior era (1985-2005).Results: BRAF status was known in 584 of 823 patients (71%). BRAF, NRAS, and C-KIT mutations were present in 51%, 22%, and 11% of tested patients, respectively. The median time from primary diagnosis to brain metastasis was 32 months, and overall median survival (MS) from the time of initial treatment of brain metastases was 10 months. MS for BRAF-positive and BRAF-negative patients was 13 months and 9 months, respectively (P=.02). There was no significant difference in MS in patients with or without NRAS or C-KIT mutations. The time from primary diagnosis to brain metastasis did not vary by mutation and was not associated with survival after the diagnosis of brain metastases. MS for the 1985 to 2005 and 2006 to 2015 cohorts was 6.7 months and 10.0 months, respectively (P<.01). Reflecting treatment-trend changes, use of whole-brain radiation therapy decreased from 48% to 26% during this period. Among BRAF-positive patients, 71% received targeted BRAF and/or MEK inhibitors and 57% received some combination of targeted therapy, chemotherapy, and/or immunotherapy.Conclusions: For melanoma patients with brain metastases, BRAF-positive patients survive longer than BRAF-negative patients and overall survival has improved from 1985-2005 to 2006-2015. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
16. PO36: Racial Analysis of Freedom from Biochemical Failure in Prostate Cancer Patients Treated with Low-Dose-Rate Brachytherapy Alone.
- Author
-
Kearns, Samuel J., Samanta, Santanu, Vyfhuis, Melissa, Mishra, Mark, Guerrero, Mariana, Amin, Pradip, Kwok, Young, and Molitoris, Jason K.
- Subjects
- *
PROSTATE cancer patients , *RADIOISOTOPE brachytherapy , *LIBERTY - Published
- 2021
- Full Text
- View/download PDF
17. PO16: Clinical Outcomes of HDR Brachytherapy with Concurrent Interstitial Hyperthermia for Gynecologic Malignancies.
- Author
-
Berger, Melanie, Pollock, Ariel E., Cohen, Justin, Rodrigues, Dario, Guerrero, Mariana, DeCesaris, Cristina, Molitoris, Jason K., Kunaprayoon, Dan, Nichols, Elizabeth M., Vujaskovic, Zeljko, and Mohindra, Pranshu
- Subjects
- *
TREATMENT effectiveness , *HIGH dose rate brachytherapy , *INTERSTITIAL brachytherapy , *FEVER - Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.